Khan Sameer K, Tyas Ben, Shenfine Amy, Jameson Simon S, Inman Dominic S, Muller Scott D, Reed Mike R
Northumbria Healthcare NHS Foundation Trust, Wansbeck General Hospital, Ashington, UK.
Health Education North East, Newcastle Upon Tyne, UK.
Bone Jt Open. 2022 Sep;3(9):710-715. doi: 10.1302/2633-1462.39.BJO-2022-0084.
Despite multiple trials and case series on hip hemiarthroplasty designs, guidance is still lacking on which implant to use. One particularly deficient area is long-term outcomes. We present over 1,000 consecutive cemented Thompson's hemiarthroplasties over a ten-year period, recording all accessible patient and implant outcomes.
Patient identifiers for a consecutive cohort treated between 1 January 2003 and 31 December 2011 were linked to radiographs, surgical notes, clinic letters, and mortality data from a national dataset. This allowed charting of their postoperative course, complications, readmissions, returns to theatre, revisions, and deaths. We also identified all postoperative attendances at the Emergency and Outpatient Departments, and recorded any subsequent skeletal injuries.
In total, 1,312 Thompson's hemiarthroplasties were analyzed (mean age at surgery 82.8 years); 125 complications were recorded, necessitating 82 returns to theatre. These included 14 patients undergoing aspiration or manipulation under anaesthesia, 68 reoperations (5.2%) for debridement and implant retention (n = 12), haematoma evacuation (n = 2), open reduction for dislocation (n = 1), fixation of periprosthetic fracture (n = 5), and 48 revised stems (3.7%), for infection (n = 13), dislocation (n = 12), aseptic loosening (n = 9), persistent pain (n = 6), periprosthetic fracture (n = 4), acetabular erosion (n = 3), and metastatic bone disease (n = 1). Their status at ten years is summarized as follows: 1,180 (89.9%) dead without revision, 34 (2.6%) dead having had revision, 84 (6.6%) alive with the stem unrevised, and 14 (1.1%) alive having had revision. Cumulative implant survivorship was 90.3% at ten years; patient survivorship was 7.4%.
The Thompson's stem demonstrates very low rates of complications requiring reoperation and revision, up to ten years after the index procedure. Fewer than one in ten patients live for ten years after fracture. This study supports the use of a cemented Thompson's implant as a cost-effective option for frail hip fracture patients.Cite this article: 2022;3(9):710-715.
尽管针对半髋关节置换术的设计进行了多项试验和病例系列研究,但在选择使用哪种植入物方面仍缺乏指导。一个特别欠缺的领域是长期疗效。我们展示了在十年期间连续进行的1000多例骨水泥型汤普森半髋关节置换术,并记录了所有可获取的患者和植入物的疗效。
将2003年1月1日至2011年12月31日期间接受治疗的连续队列患者标识符与来自国家数据集的X光片、手术记录、门诊信件和死亡率数据相关联。这使得能够绘制他们的术后病程、并发症、再次入院情况、重返手术室情况、翻修情况和死亡情况。我们还确定了所有在急诊科和门诊部的术后就诊情况,并记录了随后的任何骨骼损伤。
总共分析了1312例汤普森半髋关节置换术(手术时的平均年龄为82.8岁);记录了125例并发症,其中82例需要重返手术室。这些包括14例在麻醉下进行抽吸或手法操作的患者,68例因清创和保留植入物(n = 12)、血肿清除(n = 2)、脱位切开复位(n = 1)、假体周围骨折固定(n = 5)而进行的再次手术(5.2%),以及48例因感染(n = 13)、脱位(n = 12)、无菌性松动(n = 9)、持续疼痛(n = 6)、假体周围骨折(n = 4)、髋臼侵蚀(n = 3)和转移性骨病(n = 1)而翻修的柄(3.7%)。他们在十年时的状况总结如下:1180例(89.9%)死亡且未翻修,34例(2.6%)死亡且已翻修,84例(6.6%)存活且柄未翻修,14例(1.1%)存活且已翻修。十年时植入物的累积生存率为90.3%;患者生存率为7.4%。
指数手术后长达十年,汤普森柄显示出需要再次手术和翻修的并发症发生率非常低。骨折后每十名患者中存活超过十年的不到一人。本研究支持使用骨水泥型汤普森植入物作为体弱髋部骨折患者的一种经济有效的选择。引用本文:2022;3(9):710 - 715。